Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Erlotinib Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : National Cancer Institute | Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 14, 2012
Lead Product(s) : Erlotinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : National Cancer Institute | Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Erlotinib Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Genentech | Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2012
Lead Product(s) : Erlotinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Genentech | Novartis Pharmaceuticals Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Erlotinib Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2010
Lead Product(s) : Erlotinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : GSK
Deal Size : Inapplicable
Deal Type : Inapplicable